Tumor Biology

, Volume 34, Issue 6, pp 4059–4063 | Cite as

RETRACTED ARTICLE: Association between glutathione S-transferase M 1 null genotype and risk of ovarian cancer: a meta-analysis

Research Article


Though previous studies investigated the association between glutathione S-transferase M 1 (GSTM1) null genotype and ovarian cancer risk, the effect of GSTM1 null genotype on ovarian cancer risk was still unclear. To comprehensively quantify the association between GSTM1 null genotype and ovarian cancer risk, we performed a meta-analysis. Eleven studies from ten publications were identified from PubMed database. The pooled odds ratio (OR) with its 95 % confidence interval (CI) was used to assess the association. Meta-analysis of the total 11 studies showed that GSTM1 null genotype was not associated with ovarian cancer risk (OR = 1.03, 95 % CI 0.92–1.14, P = 0.625). The cumulative meta-analyses showed a trend of no association between GSTM1 null genotype and ovarian cancer risk as information accumulated by year. There was no evidence of publication bias in the meta-analysis. Meta-analysis of the 11 available studies shows that GSTM1 null genotype is not associated with ovarian cancer risk.


Ovarian cancer GSTM1 Meta-analysis Polymorphism 


Conflicts of interests



  1. 1.
    Gayther SA. Inherited risk of ovarian cancer and the implications for screening. Int J Gynecol Cancer. 2012;22 Suppl 1:S12–15.CrossRefPubMedGoogle Scholar
  2. 2.
    Hall M, Gourley C, McNeish I, Ledermann J, Gore M, Jayson G, et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer. 2013;108:250–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol. 2012;13:946–56.CrossRefPubMedGoogle Scholar
  4. 4.
    Liliac L, Amalinei C, Balan R, Grigoras A, Caruntu ID. Ovarian cancer: insights into genetics and pathogeny. Histol Histopathol. 2012;27:707–19.PubMedGoogle Scholar
  5. 5.
    Ziebarth AJ, Landen Jr CN, Alvarez RD. Molecular/genetic therapies in ovarian cancer: Future opportunities and challenges. Clin Obstet Gynecol. 2012;55:156–72.CrossRefPubMedGoogle Scholar
  6. 6.
    Bolton KL, Ganda C, Berchuck A, Pharaoh PD, Gayther SA. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (ocac). J Intern Med. 2012;271:366–78.CrossRefPubMedGoogle Scholar
  7. 7.
    Lallas TA, McClain SK, Shahin MS, Buller RE. The glutathione S-transferase M1 genotype in ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:587–90.PubMedGoogle Scholar
  8. 8.
    Baxter SW, Thomas EJ, Campbell IG. GSTM1 null polymorphism and susceptibility to endometriosis and ovarian cancer. Carcinogenesis. 2001;22:63–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45:51–88.CrossRefPubMedGoogle Scholar
  10. 10.
    Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology. 2000;61:154–66.CrossRefPubMedGoogle Scholar
  11. 11.
    Sarhanis P, Redman C, Perrett C, Brannigan K, Clayton RN, Hand P, et al. Epithelial ovarian cancer: influence of polymorphism at the glutathione S-transferase GSTM1 and GSTT1 loci on P53 expression. Br J Cancer. 1996;74:1757–61.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hengstler JG, Kett A, Arand M, Oesch-Bartlomowicz B, Oesch F, Pilch H, et al. Glutathione S-transferase T1 and M1 gene defects in ovarian carcinoma. Cancer Lett. 1998;130:43–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Goodman JE, Lavigne JA, Hengstler JG, Tanner B, Helzlsouer KJ, Yager JD. Catechol-o-methyltransferase polymorphism is not associated with ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9:1373–6.PubMedGoogle Scholar
  14. 14.
    Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. Carcinogenesis. 2001;22:67–72.CrossRefPubMedGoogle Scholar
  15. 15.
    Morari EC, Lima AB, Bufalo NE, Leite JL, Granja F, Ward LS. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J Cancer Res Clin Oncol. 2006;132:521–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Gates MA, Tworoger SS, Terry KL, Titus-Ernstoff L, Rosner B, De Vivo I, et al. Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:2436–44.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Khokhrin DV, Khrunin AV, Moiseev AA, Gorbunov VA. Limborskaia SA: [Association of polymorphisms in glutathione-S-transferase and DNA repair genes with ovarian cancer risk in the Russian population]. Genetika. 2012;48:901–4.PubMedGoogle Scholar
  18. 18.
    Oliveira C, Lourenco GJ, Sagarra RA, Derchain SF, Segalla JG, Lima CS. Polymorphisms of glutathione S-transferase Mu 1 (GSTM1), Theta 1 (GSTT1), and Pi 1 (GSTP1) genes and epithelial ovarian cancer risk. Dis Markers. 2012;33:155–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  21. 21.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  22. 22.
    Muellerleile P, Mullen B. Sufficiency and stability of evidence for public health interventions using cumulative meta-analysis. Am J Public Health. 2006;96:515–22.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Egger M. Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Attia J, Thakkinstian A, D'Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 2003;56:297–303.CrossRefPubMedGoogle Scholar
  25. 25.
    Wang B, Huang G, Wang D, Li A, Xu Z, Dong R, et al. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol. 2010;53:508–18.CrossRefPubMedGoogle Scholar
  26. 26.
    Zhu Y, He Q, Wang J, Pan HF. The association between GSTM1 polymorphism and gastric cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:685–91.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Department of GynecologyShanghai First Maternity and Infant Hospital, Tongji University School of MedicineShanghaiChina

Personalised recommendations